BlackRock’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $80.7M | Buy |
4,365,553
+4,038,471
| +1,235% | +$63.8M | ﹤0.01% | 2356 |
|
|
2026
Q1 | $4.88M | Buy |
327,082
+37,511
| +13% | +$587K | ﹤0.01% | 3839 |
|
|
2025
Q4 | $5.26M | Buy |
289,571
+135,320
| +88% | +$2.28M | ﹤0.01% | 3819 |
|
|
2025
Q3 | $1.96M | Sell |
154,251
-1,648
| -1% | -$14.2K | ﹤0.01% | 4094 |
|
|
2025
Q2 | $778K | Buy |
155,899
+22,173
| +17% | +$104K | ﹤0.01% | 4339 |
|
|
2025
Q1 | $1.07M | Buy |
133,726
+491
| +0.4% | +$3.72K | ﹤0.01% | 4168 |
|
|
2024
Q4 | $990K | Buy |
133,235
+132,906
| +40,397% | +$1.42M | ﹤0.01% | 4225 |
|
|
2024
Q3 | $3.13K | Hold |
329
| – | – | ﹤0.01% | 5086 |
|
|
2024
Q2 | $4.1K | Sell |
329
-1,795
| -85% | -$23.3K | ﹤0.01% | 5144 |
|
|
2024
Q1 | $46.2K | Sell |
2,124
-13,752
| -87% | -$74.1K | ﹤0.01% | 4888 |
|
|
2023
Q4 | $144K | Buy |
15,876
+15,440
| +3,541% | +$348K | ﹤0.01% | 4718 |
|
|
2023
Q3 | $12.6K | Sell |
436
-83
| -16% | -$3.71K | ﹤0.01% | 5185 |
|
|
2023
Q2 | $44.2K | Buy |
519
+89
| +21% | +$59.9K | ﹤0.01% | 5082 |
|
|
2023
Q1 | $180K | Hold |
430
| – | – | ﹤0.01% | 4805 |
|
|
2022
Q4 | $520K | Sell |
430
-1
| -0.2% | -$1.3K | ﹤0.01% | 4596 |
|
|
2022
Q3 | $343K | Sell |
431
-1
| -0.2% | -$1.08K | ﹤0.01% | 4828 |
|
|
2022
Q2 | $622K | Sell |
432
-876
| -67% | -$1.17M | ﹤0.01% | 4700 |
|
|
2022
Q1 | $2.73M | Sell |
1,308
-12
| -0.9% | -$30.1K | ﹤0.01% | 4263 |
|
|
2021
Q4 | $6.46M | Buy |
1,320
+29
| +2% | +$174K | ﹤0.01% | 3885 |
|
|
2021
Q3 | $8.1M | Buy |
1,291
+11
| +0.9% | +$89.2K | ﹤0.01% | 3766 |
|
|
2021
Q2 | $12.1M | Buy |
1,280
+444
| +53% | +$3.72M | ﹤0.01% | 3580 |
|
|
2021
Q1 | $7.27M | Buy |
836
+129
| +18% | +$1.22M | ﹤0.01% | 3757 |
|
|
2020
Q4 | $5.37M | Buy |
707
+20
| +3% | +$139K | ﹤0.01% | 3679 |
|
|
2020
Q3 | $4.5M | Buy |
687
+86
| +14% | +$646K | ﹤0.01% | 3624 |
|
|
2020
Q2 | $4.5M | Buy |
601
+158
| +36% | +$1.15M | ﹤0.01% | 3564 |
|
|
2020
Q1 | $3.16M | Sell |
443
-6
| -1% | -$63.5K | ﹤0.01% | 3514 |
|
|
2019
Q4 | $6.97M | Buy |
449
+14
| +3% | +$148K | ﹤0.01% | 3408 |
|
|
2019
Q3 | $4.12M | Buy |
435
+16
| +4% | +$179K | ﹤0.01% | 3539 |
|
|
2019
Q2 | $6.56M | Buy |
419
+409
| +4,090% | +$6.2M | ﹤0.01% | 3438 |
|
|
2019
Q1 | $170K | Sell |
10
-2
| -17% | -$29.9K | ﹤0.01% | 4267 |
|
|
2018
Q4 | $109K | Buy |
12
+2
| +20% | +$22.3K | ﹤0.01% | 4339 |
|
|
2018
Q3 | $133K | Hold |
10
| – | – | ﹤0.01% | 4403 |
|
|
2018
Q2 | $120K | Buy |
10
+9
| +900% | +$107K | ﹤0.01% | 4435 |
|
|
2018
Q1 | $16K | Hold |
1
| – | – | ﹤0.01% | 4591 |
|
|
2017
Q4 | $12K | Hold |
1
| – | – | ﹤0.01% | 4615 |
|
|
2017
Q3 | $3K | Hold |
1
| – | – | ﹤0.01% | 4790 |
|
|
2017
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 4894 |
|
|
2017
Q1 | $2K | Buy |
+1
| New | +$2.39K | ﹤0.01% | 4883 |
|
Other funds holding AVTX
NFT
MAP
PAP
BlackRock's AVTX Position: Q2 2026 in Review
BlackRock increased its Avalo Therapeutics (AVTX) stake by 1,235% in Q2 2026, buying an estimated $63.8M and bringing the position to 4,365,553 shares worth $80.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.
BlackRock first reported a position in AVTX in Q1 2017 and has held it in 38 quarters since. 27 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.
- BlackRock held 4,365,553 shares of Avalo Therapeutics worth $80.7M as of Q2 2026.
- BlackRock bought 4,038,471 Avalo Therapeutics shares in Q2 2026, an estimated $63.8M.
- Avalo Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2356 holding.
- BlackRock first reported a position in Avalo Therapeutics in Q1 2017 and has held it in 38 quarters since.
- 27 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.